Bionano Genomics Stock Earnings Reports

Bionano reported Q1 2026 revenue of $6.7M (up 4% YoY), driven by record Q1 flow cell unit sales of 8,178 (up 17% YoY; +21% to existing customers when excluding system-tied flow cells). Consumable revenue grew 20% YoY to $3.9M while software revenue declined due to a large prior-year software sale. Adjusted gross margin improved to 49% (from ~46% a year ago), reflecting cost efficiencies and a higher-margin revenue mix. Cash, cash equivalents and available-for-sale securities totaled $24.7M (including $10.3M restricted); management expects cash runway into 2027 and expects to fully retire outstanding senior secured convertible debt in May 2026. Management reaffirmed full-year 2026 revenue guidance of $30M–$33M and provided Q2 guidance of $7.5M–$7.8M. Key strategic drivers include prioritizing routine users for profitable consumable growth, pushing software (VIA) and Ionic adoption to increase utilization, active efforts to secure reimbursement and guideline inclusion (notably two Category 1 CPT codes and materially higher reimbursement rates effective 2026), expanding publication and clinical validation momentum (multiple high‑profile studies and increased publications/genomes), and continued focus on improving profitability toward eventual cash-flow breakeven (not expected by end of 2026). Management emphasized the transition from R&D to commercialization and scaling OGM adoption while noting remaining production constraints on flow cells are easing.